As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of Revolution Medicines Inc. The largest reported stake is Dapice Joshua J.'s, at 7.5%. 17 filings are on record since July 17, 2025 (Schedule 13G/A, February 9, 2026).
Who owns Revolution Medicines, Inc.?
Sell to companies like Revolution Medicines Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 15,129,912 · Shared voting: 0 · Sole dispositive: 15,402,103 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-11-05
- · Holder: Vanguard Capital Management · Percent: 5.13% · SCHEDULE 13G
- · Holder: Baker Bros. Advisors LP · Percent: 5.3% · SCHEDULE 13G
- · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 13,564,149 · Sole dispositive: 0 · Shared dispositive: 13,564,149 · SCHEDULE 13G/A, 2026-08-13
- · Holder: JANUS HENDERSON GROUP Ltd. · Percent: 5.1% · SCHEDULE 13G
Revolution Medicines Inc has 17 Schedule 13D or 13G filings on record since 2025-07-17. 7 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 7.5% | 14,596,149 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-31 | |
| Fmr LLC | 7.2% | 15,402,103 | SCHEDULE 13G/A, 2026-11-05 | 2026-09-30 |
| Farallon Capital Management, L.L.C. | 6.4% | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| BlackRock, Inc. | 5.7% | 12,201,395 | SCHEDULE 13G, 2026-07-29 | 2026-06-30 |
| Baker Bros. Advisors LP | 5.3% | 11,443,357 | SCHEDULE 13G, 2026-08-14 | 2026-06-30 |
| Vanguard Capital Management | 5.13% | 10,999,044 | SCHEDULE 13G, 2026-10-30 | 2026-09-30 |
| JANUS HENDERSON GROUP Ltd. | 5.1% | 10,736,145 | SCHEDULE 13G, 2026-08-13 | 2026-06-30 |
| Wellington Management Group LLP | 3.6% | 6,987,639 | SCHEDULE 13G/A, 2026-02-10 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Revolution Medicines Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Revolution Medicines Inc and the records around it.
Revolution Medicines Inc elsewhere on the record
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
Watch Revolution Medicines Inc
Get an email when Revolution Medicines Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Revolution Medicines Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Revolution Medicines Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Revolution Medicines Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Fmr LLC | 15,129,912 | 0 | 15,402,103 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 15,402,103 | 0 | SCHEDULE 13G/A, 2026-11-05 |
| Farallon Capital Management, L.L.C. | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Institutional Partners III, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Four Crossings Institutional Partners V, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital Offshore Investors II, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital (AM) Investors, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Capital F5 Master I, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Healthcare Partners Master, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Partners, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Institutional (GP) V, L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon F5 (GP), L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Farallon Healthcare Partners (GP), L.L.C. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Dapice Joshua J. | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
| Dreyfuss, Philip D. | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
| Dunn Hannah E. | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
| Gehani, Varun N. | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
| Giauque, Nicolas | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
| Husen, Avner A. | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
| Kim, David T. | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
| Linn, Michael G. | 0 | 13,564,149 | 0 | 13,564,149 | SCHEDULE 13G/A, 2026-08-13 |
The latest filing identifies Revolution Medicines Inc by CUSIP 76155X100 and gives its principal executive office as 700 Saginaw Dr., Redwood City, CA 94063 (SCHEDULE 13G/A, 2026-11-05).
What the percentages are based on
The information in Item 11 of each of the cover pages to this Schedule 13G is incorporated herein by reference.Baker Bros. Advisors LP, SCHEDULE 13G, 2026-08-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-17 | BlackRock, Inc. | 4.5% | SCHEDULE 13G/A |
| 2025-08-12 | Wellington Management Group LLP | 5.5% | SCHEDULE 13G/A |
| 2025-08-14 | Baker Bros. Advisors LP | 5% | SCHEDULE 13G |
| 2025-08-14 | Janus Henderson Group Plc | 5.7% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 5% | SCHEDULE 13G |
| 2025-11-14 | Janus Henderson Group Plc | 6.1% | SCHEDULE 13G/A |
| 2026-02-09 | Dapice Joshua J. | 7.5% | SCHEDULE 13G/A |
| 2026-02-10 | Wellington Management Group LLP | 3.6% | SCHEDULE 13G/A |
| 2026-02-17 | Baker Bros. Advisors LP | 4.9% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 4.9% | SCHEDULE 13G/A |
| 2026-07-29 | BlackRock, Inc. | 5.7% | SCHEDULE 13G |
| 2026-08-13 | Farallon Capital Management, L.L.C. | 6.4% | SCHEDULE 13G/A |
| 2026-08-13 | JANUS HENDERSON GROUP Ltd. | 5.1% | SCHEDULE 13G |
| 2026-08-14 | Baker Bros. Advisors LP | 5.3% | SCHEDULE 13G |
| 2026-10-30 | Vanguard Capital Management | 5.13% | SCHEDULE 13G |
| 2026-11-05 | Fmr LLC | 7.2% | SCHEDULE 13G/A |
Questions about who owns Revolution Medicines Inc
Who owns Revolution Medicines Inc?
On this page, 7 holders' latest ownership filings report 5% or more of Revolution Medicines Inc: Dapice Joshua J. (7.5%, Schedule 13G/A, filed 2026-02-09), Fmr LLC (7.2%, Schedule 13G/A, filed 2026-11-05), Farallon Capital Management, L.L.C. (6.4%, Schedule 13G/A, filed 2026-08-13), BlackRock, Inc. (5.7%, Schedule 13G, filed 2026-07-29) and Baker Bros. Advisors LP (5.3%, Schedule 13G, filed 2026-08-14); 2 more are listed above.
Who are the largest shareholders of Revolution Medicines Inc?
By the share each holder's latest filing reports, the largest holders of Revolution Medicines Inc on this page are Dapice Joshua J. (7.5%), Fmr LLC (7.2%) and Farallon Capital Management, L.L.C. (6.4%).
When did Dapice Joshua J. buy into Revolution Medicines Inc?
The filings give report dates, not purchase dates. The earliest filing from Dapice Joshua J. on this page is the Schedule 13G/A, filed 2026-02-09, reporting 7.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Revolution Medicines Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.